Dapagliflozin May Be Cost-Effective for Treating CKD
FRIDAY, Nov. 4, 2022 -- Dapagliflozin seems to be cost-effective in the United Kingdom, Germany, and Spain for patients meeting the eligibility criteria for the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD)...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Chronic Kidney Disease | Dapagliflozin | Forxiga | Germany Health | Pharmaceuticals | Spain Health | UK Health | Urology & Nephrology